Company Profile: Merck & Co., Inc. (MRK)

MRK insider trades (13 months) →

$144.67 −2.49% vs. previous close · Market cap $356.93B

Today's multi-factor rank: 184 of 461 · see the ranking

Quant500 Scores

Momentum

8.0/10

Value

3.8/10

Growth

3.7/10

Quality

4.8/10

Multifactor

5.1/10

Market and Valuation

Price & Market

Prev Close Price:$148.36

Open:$147.01

Day's Low:$143.47

Day's High:$147.62

Bid / Ask:-

Market Cap:356.93B

Enterprise Value:412.85B

52-Week Range

52-Week Low:$82.01

52-Week High:$156.92

Current position in 52-week range

52w Low-52w High

50-Day Avg:$146.78

200-Day Avg:$126.89

Volume

Volume Today:8,862,415

Avg Volume (3m):10,332,142

Avg Volume (10d):11,160,100

52-Week Change:+76.91%

vs S&P 500, 52 weeks:-

Beta:0.12

Valuation Multiples

P/E (trailing):146.13

12-month EPS and P/E from the market data provider (Yahoo Finance), not from the SEC: the latest quarter with EPS at the SEC ended Jun 30, 2026, more than 120 days ago.

P/E (forward):16.03

PEG Ratio:2.80

Price / Book:8.52

Price / Sales (TTM):5.30

EV / Revenue:6.13

EV / EBITDA:25.86

Dividends

Current yield:2.29%

Annual Dividend Rate:$3.40

Dividend Trailing:$3.36

Yield Trailing:2.26%

5-Year Avg Yield:2.87%

Payout Ratio:266.67%

Last Ex-Dividend Date:-

Valuation Context

P/E vs sector (indicative)

Most Recent Quarter:-

Fiscal Year (Next):-

Date Filter (Month):

Loading historical OHLCV database...

Financial Statements TTM (Trailing 12 Months)

Income Statement

Total Revenue (TTM):67.38B

Gross Profit:51.82B

EBITDA:15.96B

Net Income (TTM):2.45B

Rev Growth (YoY):+4.70%

Earnings Growth (YoY):-12.00%

Quarterly earnings growth (YoY):-12.40%

Margins

Gross Margin:-

EBITDA Margin:-

Operating Margin:-

Net Margin:-

Per Share

EPS Trailing (TTM):$0.99

12-month EPS and P/E from the market data provider (Yahoo Finance), not from the SEC: the latest quarter with EPS at the SEC ended Jun 30, 2026, more than 120 days ago.

EPS Forward (Est.):$9.02

Revenue Per Share:$27.28

Cash Per Share:-

Book Value:$16.99

Last Dividend:-

Ex-Dividend Date:-

Last Split:-

Balance Sheet & Liquidity

Total cash:7.14B

Total Debt:53.91B

Net Debt (Debt - Cash):46.77B

Debt / Equity:128.41%

Current Ratio:-

Quick Ratio:-

Cash Flows

Operating Cash Flow:-

Free Cash Flow (FCF):-

FCF Yield (FCF / Market Cap):-

Enterprise Value:412.85B

EV / Revenue:6.13

EV / EBITDA:25.86

Profitability

ROE (Return on Equity):-

ROA (Return on Assets):-

P/E (trailing):146.13

P/E (forward):16.03

Price / Book:8.52

PEG Ratio:2.80

52-Week Change:+76.91%

S&P 500 change, 52 weeks:+11.37%

Historical Evolution (Last 4 Years)

Income Statement

Balance Sheet

Cash Flow

EPS and Earnings Per Share

Key EPS Metrics

EPS Trailing (TTM):$0.99

12-month EPS and P/E from the market data provider (Yahoo Finance), not from the SEC: the latest quarter with EPS at the SEC ended Jun 30, 2026, more than 120 days ago.

EPS Forward (Est.):$9.02

P/E (forward):16.03

PEG Ratio:2.80

Growth and Margins

Earnings Growth YoY:-

Quarterly Earnings Growth YoY:-

Rev Growth YoY:-

Net Margin:-

Gross Margin:-

EBITDA Margin:-

Per Share

Revenue Per Share:$27.28

Cash Per Share:-

Book Value:$16.99

Cash Flows (TTM)

Free Cash Flow:-

Operating Cash Flow:-

EBITDA:15.96B

Total Revenue (TTM):67.38B

Net Income (TTM):2.45B

Fiscal Year (Last):-

EPS Surprise History - Last 4 Quarters

Actual vs. Analyst Estimates · Green = beat expectations · Red = missed

Quarter	Period	Actual EPS	Estimated EPS	Difference	Surprise %	Currency

Ownership Structure

Ownership Distribution

% Insiders:-

% Institutional:-

% Inst. (of Float):-

No. of Institutions:-

Visual distribution

InsidersInstitutionalFree Float

Shares & Short Interest

Shares Outstanding:2,467,171,638

Float (free shares):2,463,026,790

Short interest (shares):26,825,098

Short % of float:-

Short Ratio (days to cover):2.68

Short interest, prior month:-

Short Interest Date:-

Governance Score (1=Best, 10=Worst)

Overall risk:-

Audit Risk:-

Board risk:-

Compensation Risk:-

Shareholder rights risk:-

Top Institutional Holders

Position Change: ▲ Increased · ▼ Reduced · = Unchanged

Organization	Report Date	% Shares	No. Shares	Value (USD)	Change %

Top Mutual Funds

Position Change: ▲ Increased ▼ Decreased = Unchanged

Fund	Report Date	% Shares	No. Shares	Value (USD)	Change %

Recent Insider Trades

Executive / Insider	Title	Date	Action	Shares

Options Chain

Expiration Date:

CALLS

Strike	Last	Bid	Ask	Vol.	O.I.	IV

PUTS

Strike	Last	Bid	Ask	Vol.	O.I.	IV

Merck & Co., Inc. (MRK) SEC filings: 10-K, 10-Q and 8-K

Direct links to financial reports filed with the SEC.

Type	Date	Official link
8-K	2026-10-29	View filing ↗
25-NSE	2026-10-15	View filing ↗
8-K	2026-10-13	View filing ↗
8-K	2026-08-04	View filing ↗
11-K	2026-06-24	View filing ↗
SD	2026-05-29	View filing ↗
8-K	2026-05-28	View filing ↗
8-K	2026-05-22	View filing ↗
SC TO-T/A	2026-05-05	View filing ↗
10-Q	2026-05-04	View filing ↗

Company and Executive Profile

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

General Information

Headquarters:United States

City:Rahway

Employees:73,000

Sector:Healthcare

Industry:Drug Manufacturers - General

Website:-

Key Executives

Name	Title	Age	Total pay
Mr. Robert M. Davis J.D.	Chairman, President & CEO	58	4.63M
Ms. Caroline A. Litchfield	Executive VP & CFO	56	2.40M
Ms. Jennifer L. Zachary J.D.	Executive VP & General Counsel	47	2.17M
Dr. Dean Y. Li M.D., Ph.D.	Executive VP & President of Merck Research Laboratories	62	3.00M
Mr. Dalton E. Smart III	Senior VP of Finance, Principal Accounting Officer & Global Controller	58	-
Mr. Gaurav K. Gupta	Executive Vice President and Chief Information & Digital Officer	-	-
Mr. Peter Dannenbaum	Vice President of Investor Relations	-	-
Mr. Chirfi Guindo	Executive Vice President of Strategic Access, Policy & Communications	59	1.54M

You have seen the engine room

A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.

No card. No spam.

Merck & Co., Inc. (MRK): Quantitative Analysis

Name: Factor scores for Merck & Co., Inc. (MRK)
Creator: Quant500
License: https://quant500.com/legal

Merck & Co., Inc. (MRK) — Healthcare — Drug Manufacturers - General. MRK is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.

So far in 2026, MRK has returned +39.9% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.

MRK ranks 184 of 461 on today's multifactor score, and 22 of the 55 Healthcare companies that score. Its strongest factor is momentum (Z 1.81, ranked 24 of 494); its weakest is growth (Z -0.81, ranked 467 of 489). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.

Factor scores

The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.

Factor	Z-Score	Rank
Multifactor	0.032	184 of 461
Momentum	1.810	24 of 494 ↓7
Value	-0.727	460 of 489
Quality	-0.149	261 of 468
Growth	-0.808	467 of 489

Market data

Metric	Value
Price	$144.67
Market Cap	356.93B
P/E	146.13
Revenue (last 12 months)	67.38B
Price / book	8.52
Book value per share	$16.99
52-week range	$82.01 – $156.92
Dividend yield	2.29%
Beta	0.12
Average volume	10,332,142
Shares outstanding	2.47B
Short interest (% of float)	1.09% (as of Oct 15, 2026)

When does MRK report earnings? 11 of its last 11, before the open →

What are MRK insiders doing? 72 transactions filed with the SEC, of them 23 sells, the last one on Aug 13, 2026 →

MRK latest SEC filings

Annual report (10-K): filed Feb 24, 2026, fiscal year ended Dec 31, 2025 · view the filing on sec.gov
Quarterly report (10-Q): filed Aug 7, 2026, quarter ended Jun 30, 2026 · see its 10-Q filings on sec.gov
Earnings release (8-K): Oct 29, 2026, before the open · view the 8-K on sec.gov

Filing dates on EDGAR, the SEC's public registry. All MRK filings on EDGAR.

Guides: How to read a Quant500 company page · What the S&P 500 is · P/E ratio explained · 10-K, 10-Q and 8-K · all guides

Frequently asked questions about Merck (MRK)

When does Merck report earnings?

Merck has no announced date in the Nasdaq public calendar checked (Nov 3, 2026 to Dec 7, 2026). Of its last 12 earnings announcements: 11 before the open (and 1 with no time on the filing) (SEC filings through Oct 29, 2026). MRK earnings dates and times, quarter by quarter →

What is Merck's P/E ratio?

Merck's P/E (price over earnings per share for the last twelve months) is 146.1 at the Nov 3, 2026 close. That EPS is the 12-month figure from the market data provider (Yahoo Finance), not the SEC one. The median of the 54 Healthcare companies with a P/E is 30.5, and the S&P 500's, 23.5: Merck is above its sector median. Healthcare stocks, company by company →

Where does Merck rank on Quant500?

In the Nov 3, 2026 multi-factor ranking, Merck ranks 184 of 461, and 22 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking → How it is calculated →

Have Merck insiders bought or sold shares?

SEC Form 4 shows no open-market purchase of Merck shares from August 2025 through Nov 3, 2026. The latest sale was on Aug 13, 2026, by an officer, for $1.4M. In total, from August 2025 through Nov 3, 2026: 0 purchases and 23 sales by directors, officers and large shareholders. All MRK insider trades →

Does Merck pay a dividend?

Yes. Its dividend yield is 2.29% at the Nov 3, 2026 close (annual dividend of $3.40 per share). The latest recorded ex-dividend date is Sep 15, 2026.

What sector is Merck in, and which index?

Merck is classified in the Healthcare sector (industry: Drug Manufacturers - General), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →

What is behind these numbers

The concepts on this page, explained from scratch in the Academy. Free, no account.

Valuation multiples: P/E, P/B, EV/EBITDA and their trapsWhy the P/E and the price-to-book in the table above cannot be compared across sectors, and what a low P/E can hide.
Value and momentum: the two that have survived bestWhat the value and momentum scores on this page actually measure, and why they are the two factors that have best survived scrutiny.
Quality and low volatilityWhere the quality score comes from, and why it is the factor with the most competing definitions, all of them called the same thing.
Sales growth: the driver that gets overestimated mostWhat sits behind the growth score and the twelve-month revenue, and why it is the number people extrapolate too far most often.
Dividends and payout: high is not always goodThis company pays a dividend and its yield is in the table above: when a high figure is good news and when it is a warning.

The whole Academy, course by course →

Data as of Nov 3, 2026. Source: point-in-time SEC fundamentals and closing prices. Method and formulas are on the home page.

Company Profile: Merck & Co., Inc. (MRK)

Market and Valuation

Price & Market

52-Week Range

Volume

Valuation Multiples

Dividends

Valuation Context

Financial Statements TTM (Trailing 12 Months)

Income Statement

Margins

Per Share

Balance Sheet & Liquidity

Cash Flows

Profitability

Historical Evolution (Last 4 Years)

Income Statement

Balance Sheet

Cash Flow

EPS and Earnings Per Share

Key EPS Metrics

Growth and Margins

Per Share

Cash Flows (TTM)

EPS Surprise History - Last 4 Quarters

Ownership Structure

Ownership Distribution

Shares & Short Interest

Governance Score (1=Best, 10=Worst)

Top Institutional Holders

Top Mutual Funds

Recent Insider Trades

Options Chain

CALLS

PUTS

Sentiment Metrics

Expected move

Merck & Co., Inc. (MRK) SEC filings: 10-K, 10-Q and 8-K

Company and Executive Profile

General Information

Key Executives

You have seen the engine room

Merck & Co., Inc. (MRK): Quantitative Analysis

Factor scores

Market data

MRK latest SEC filings

Frequently asked questions about Merck (MRK)

When does Merck report earnings?

What is Merck's P/E ratio?

Where does Merck rank on Quant500?

Have Merck insiders bought or sold shares?

Does Merck pay a dividend?

What sector is Merck in, and which index?

What is behind these numbers